Todos Medical - Full Color Logo
  • R&D Pipeline
    • Proprietary Diagnostics
      • Videssa® Breast: Cancer Blood Test
      • LymPro™: Alzheimer's Blood Test
      • TolloTest™: Coronavirus 3CL Protease Test
      • TBIA: AI Cancer Platform
    • Antiviral Drug Development
      • Tollovir™: 3CL Protease Inhibitor
  • Products & Services
    • Lab Solutions
      • Provista Diagnostics: CLIA/CAP Lab
      • COVID Testing: Lab Supplies & Automated Solutions
    • Dietary Supplement
      • Tollovid™: 3CL Protease Inhibitor
  • Insights
    • Publications
    • News & Media
    • Downloads
    • How It Works: 3CL Protease Inhibitors
    • Case Study: Lab Automation
  • Investors
  • About
    • Management Team
    • Board of Directors
    • Advisors
    • Career Opportunities
    Add a button link here
    Contact Us

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Governance Documents
    • News & Events

    • Press Releases
    • IR Calendar
    • Email Alerts
    Aug 23, 2021 7:20am EDT

    Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity

    Aug 17, 2021 7:39am EDT

    Todos to Present at Upcoming Emerging Growth Conference

    Aug 05, 2021 10:40am EDT

    Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™

    Aug 05, 2021 9:32am EDT

    Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™

    Aug 02, 2021 7:32am EDT

    Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition

    Jul 28, 2021 8:57am EDT

    Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir

    Jul 22, 2021 9:00am EDT

    Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim

    Jul 19, 2021 8:31am EDT

    Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma

    Jul 07, 2021 9:20am EDT

    Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller

    Jun 29, 2021 10:44am EDT

    Todos Medical Provides End of Second Quarter 2021 Corporate Update

    • arrow_back
    • 1…
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • …20
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Company Profile
    • Contacts
    • RSS News Feed

    Todos Medical - Full Color-1

     

    About Us

    Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s Disease, and the distribution of comprehensive solutions for COVID-19 screening.

    OTCQB: TOMDF

    Contact Us

    Todos Medical Ltd.
    121 Derech Menachem Begin

    30th Floor
    Tel Aviv, Israel 6701203
    Phone: +972-73-207-7259

    Todos Medical U.S.A.
    40 Wall Street, Suite 2702

    New York, NY 10005
    Phone: +1-917-983-4229

    Sign Up

    Follow us on Twitter Follow us on Facebook Follow us on LinkedIn
    © 2022 Todos Medical. All rights reserved.